Lantheus

Q2 FY2026 EarningsQ2 FY26 results beat consensus across the board, with revenue of $388.2M exceeding the $363.2M estimate (+6.88%) and Adjusted EPS of $1.55 vs. the $1.30 mean (+18.94%). Despite a 4.1% YoY decline in PYLARIFY sales, the company achieved total top-line growth of 2.7% YoY, bolstered by the new Neuraceq segment ($39.6M). The announcement of a definitive merger agreement with Curium at up to $114.50 per share effectively anchors the stock's valuation, leading to the suspension of full-year guidance.